- Home
- ARVN vs TNXP Comparison
ARVN vs TNXP Comparison
Compare ARVN & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- TNXP
- Stock Information
- Founded
- ARVN 2015
- TNXP 2007
- Country
- ARVN United States
- TNXP United States
- Employees
- ARVN N/A
- TNXP N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- ARVN Health Care
- TNXP Health Care
- Exchange
- ARVN Nasdaq
- TNXP Nasdaq
- Market Cap
- ARVN 456.2M
- TNXP 335.6M
- IPO Year
- ARVN 2018
- TNXP N/A
- Fundamental
- Price
- ARVN $6.79
- TNXP $59.76
- Analyst Decision
- ARVN Buy
- TNXP Buy
- Analyst Count
- ARVN 22
- TNXP 1
- Target Price
- ARVN $20.21
- TNXP $70.00
- AVG Volume (30 Days)
- ARVN 2.1M
- TNXP 1.6M
- Earning Date
- ARVN 08-06-2025
- TNXP 08-11-2025
- Dividend Yield
- ARVN N/A
- TNXP N/A
- EPS Growth
- ARVN N/A
- TNXP N/A
- EPS
- ARVN N/A
- TNXP N/A
- Revenue
- ARVN $372,800,000.00
- TNXP $9,831,000.00
- Revenue This Year
- ARVN $7.57
- TNXP $22.87
- Revenue Next Year
- ARVN N/A
- TNXP $711.66
- P/E Ratio
- ARVN N/A
- TNXP N/A
- Revenue Growth
- ARVN 299.57
- TNXP N/A
- 52 Week Low
- ARVN $5.90
- TNXP $6.76
- 52 Week High
- ARVN $29.61
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- ARVN 41.59
- TNXP 70.74
- Support Level
- ARVN $6.06
- TNXP $44.10
- Resistance Level
- ARVN $7.83
- TNXP $48.50
- Average True Range (ATR)
- ARVN 0.40
- TNXP 5.16
- MACD
- ARVN -0.11
- TNXP 0.77
- Stochastic Oscillator
- ARVN 34.93
- TNXP 94.36
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.